

V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION
POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case M.8237 — Johnson & Johnson/Abbott Medical Optics)

(Text with EEA relevance)

(2017/C 23/08)

1. On 17 January 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ⁽¹⁾ by which Johnson & Johnson ('J&J', United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Abbott Medical Optics Inc. ('AMO', United States) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

- for J&J: the provision of pharmaceutical products, medical devices and consumer healthcare products through a global group of companies,
- for AMO: the global provision of medical devices for cataract and refractive surgery as well as ophthalmic healthcare products.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8237 — Johnson & Johnson/Abbott Medical Optics, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

⁽¹⁾ OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').